Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 12/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656223 | 0.88 | PYGL (0.60) | GRIN1GRIN2BKCNH2PYGLKMT2A | |
| SCHEMBL13656210 | 0.86 | KMT2A (0.56) | GRIN1GRIN2BKCNH2PYGLKMT2A | |
| SCHEMBL13656205 | 0.85 | GRIN1 (0.52) | GRIN1GRIN2BKCNH2PYGLKMT2A | |
| SCHEMBL13656111 | 0.84 | GRIN1 (0.67) | GRIN1GRIN2BKCNH2KMT2AMAPT | |
| SCHEMBL2016866 | 0.81 | GRIN1 (0.73) | GRIN1GRIN2BKCNH2PYGLFFAR1 | |
| SCHEMBL13656270 | 0.81 | GRIN1 (0.60) | GRIN1GRIN2BKCNH2KMT2ACA1 | |
| SCHEMBL13656209 | 0.80 | GRIN1 (0.67) | GRIN1GRIN2BKCNH2PYGLKMT2A | |
| SCHEMBL1422262 | 0.78 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2PYGLMAPT | |
| SCHEMBL8006356 | 0.78 | GRIN1 (0.69) | GRIN1GRIN2BKCNH2PYGLKMT2A | |
| SCHEMBL14864573 | 0.78 | GRIN1 (0.62) | GRIN1GRIN2BKCNH2PYGLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885KCNH2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.